Generate Biomedicines prices IPO at USD 400m, begins trading on Nasdaq

Generate Biomedicines, Inc. (Nasdaq: GENB), a clinical-stage generative biology company based in Somerville, Massachusetts, announced the pricing of its initial public offering. The Generate Biomedicines IPO consists of 25,000,000 shares of common stock priced at USD 16.00 per share, with expected gross proceeds of USD 400 million before expenses. GENB stock began trading on the Nasdaq Global Select Market on February 27, 2026, with the offering expected to close on March 2, 2026, subject to customary closing conditions.

The IPO pricing includes a 30-day overallotment option granted to the underwriters to purchase up to an additional 3,750,000 shares at the IPO price. If exercised in full, total gross proceeds would reach USD 460 million. Goldman Sachs & Co. LLC and Morgan Stanley are acting as joint lead book-running managers, with Piper Sandler, Guggenheim Securities, and Cantor serving as additional book-running managers.

Company Overview and Pipeline

Generate Biomedicines was founded in 2018 by Flagship Pioneering, the life sciences venture capital firm also known for creating Moderna. The company’s core technology asset is CHROMA, a proprietary generative artificial intelligence platform designed for de novo protein drug design. The platform uses diffusion-based and language model architectures trained on protein structure and sequence data to generate novel protein therapeutics. The scientific basis for CHROMA was described in a 2023 publication in Nature.

Prior to the IPO, Generate Bio raised approximately USD 693 million across private funding rounds. Flagship Pioneering led each round, including a Series A of approximately USD 50 million in 2020, a Series B of approximately USD 370 million in 2021 with participation from T. Rowe Price and Altitude Life Science Ventures, and a Series C of approximately USD 273 million in 2022. The company also entered into two partnership deals that provided non-dilutive capital: a collaboration with Amgen in 2022 and a collaboration and license agreement with Novartis in 2023. The Novartis deal included an upfront payment of USD 152 million and potential milestone payments of up to approximately USD 1.9 billion per exclusive target, covering programs in immunology and oncology.

The company’s clinical pipeline includes multiple candidates designed using the CHROMA platform. The most advanced program is GB-0895, an anti-TSLP antibody in development for severe uncontrolled asthma. Two Phase III trials, designated SOLAIRIA-1 and SOLAIRIA-2, are currently recruiting, with target enrollment of 786 patients each and primary endpoints measuring annualized asthma exacerbation rate. Both studies have estimated completion dates in late 2028 and early 2029, respectively. GB-0895 is also being evaluated in a Phase I study in patients with mild-to-moderate asthma or COPD, which is active but no longer recruiting, with an estimated completion date of May 2027.

A second clinical candidate, GB-7624, is in a Phase I study in healthy volunteers evaluating safety and pharmacokinetics, with an estimated completion date of December 2026. This program is directed toward atopic dermatitis. Additional earlier-stage programs referenced in SEC filings include GB-1045, a Claudin 18.2 × CD3 bispecific T-cell engager in Phase I for gastric and pancreatic cancers, and GB-3250, a TL1A-targeting monoclonal antibody in Phase I for inflammatory bowel disease.

Generate Biomedicines, as designated by its Nasdaq ticker GENB, enters the public markets with a pipeline spanning oncology, respiratory disease, and immunology, all derived from its AI-driven protein design platform, and with prior validation through its Novartis and Amgen collaborations.